

# PUBLISHED VERSION

Greg Hodge, Mark Holmes, Hubertus Jersmann, Paul N. Reynolds and Sandra Hodge  
**The drug efflux pump Pgp1 in pro-inflammatory lymphocytes is a target for novel treatment strategies in COPD**  
Respiratory Research (Online), 2013; 14(63):1-8

© 2013 Hodge et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Originally published at:  
<http://doi.org/10.1186/1465-9921-14-63>

## PERMISSIONS

<http://creativecommons.org/licenses/by/2.0/>



This is a human-readable summary of (and not a substitute for) the [license](#).

[Disclaimer](#)



### You are free to:

- Share** — copy and redistribute the material in any medium or format
- Adapt** — remix, transform, and build upon the material  
for any purpose, even commercially.

The licensor cannot revoke these freedoms as long as you follow the license terms.

### Under the following terms:



**Attribution** — You must give [appropriate credit](#), provide a link to the license, and [indicate if changes were made](#). You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

**No additional restrictions** — You may not apply legal terms or [technological measures](#) that legally restrict others from doing anything the license permits.

<http://hdl.handle.net/2440/79628>

RESEARCH

Open Access

# The drug efflux pump Pgp1 in pro-inflammatory lymphocytes is a target for novel treatment strategies in COPD

Greg Hodge<sup>1,2\*</sup>, Mark Holmes<sup>1,2</sup>, Hubertus Jersmann<sup>1,2</sup>, Paul N Reynolds<sup>1,2</sup> and Sandra Hodge<sup>1,2</sup>

## Abstract

**Background:** Pro-inflammatory/cytotoxic T cells (IFN $\gamma$ , TNF $\alpha$ , granzyme B+) are increased in the peripheral circulation in COPD. NKT-like and NK cells are effector lymphocytes that we have also shown to be major sources of pro-inflammatory cytokines and granzymes. P-glycoprotein 1 (Pgp1) is a transmembrane efflux pump well characterised in drug resistant cancer cells. We hypothesized that Pgp1 would be increased in peripheral blood T, NKT-like and NK cells in patients with COPD, and that this would be accompanied by increased expression of IFN $\gamma$ , TNF $\alpha$  and granzyme B. We further hypothesized that treatment with cyclosporine A, a Pgp1 inhibitor, would render cells more sensitive to treatment with corticosteroids.

**Methods:** Pgp1, granzyme B, IFN $\gamma$  and TNF $\alpha$  expression were measured in peripheral blood T, NK and NKT-like cells from COPD patients and control subjects ( $\pm$  cyclosporine A and prednisolone) following *in vitro* stimulation and results correlated with uptake of efflux dye Calcein-AM using flow cytometry.

**Results:** There was increased Pgp1 expression by peripheral blood T, NKT-like and NK cells co-expressing IFN $\gamma$ , TNF $\alpha$  and granzyme B in COPD patients compared with controls (e.g. %IFN $\gamma$ /Pgp1 T, NKT-like, NK for COPD (Control): 25(6), 54(27), 39(23)). There was an inverse correlation between Pgp1 expression and Calcein-AM uptake. Treatment with 2.5 ng/ml cyclosporin A and 10<sup>-6</sup> M prednisolone resulted in synergistic inhibition of pro-inflammatory cytokines in Pgp1 + cells ( $p < 0.05$  for all).

**Conclusions:** Treatment strategies that target Pgp1 in T, NKT-like and NK cells may reduce systemic inflammatory mediators in COPD and improve patient morbidity.

**Keywords:** COPD, Pgp1, Pro-inflammatory lymphocytes, Granzyme B

## Background

COPD is predicted to be the 3rd leading cause of death worldwide by 2020 [1]. Existing treatments are largely symptomatic and the only approved anti-inflammatory medication, corticosteroids, has no proven disease modifying effect [1]. Inhaled corticosteroids have major benefits for the treatment of airway inflammation in asthma, but the reason for their relative lack of efficacy in COPD is both poorly understood and a major limiting factor in COPD treatment. Thus, better understanding of the mechanisms underlying steroid resistance in COPD, and

a way to circumvent this to take better advantage of existing therapies would have an immediate clinical impact.

COPD is a systemic disease and may represent a “spill-over” of inflammatory events occurring in the lungs [2]. In this regard we have previously shown an increase in pro-inflammatory/cytotoxic T cells, NKT-like and NK cells in the peripheral blood and airways in COPD patients compared with non-COPD smokers where some changes were only noted in the lungs compared with healthy controls [3-5].

P-glycoprotein 1 (Pgp1) is a transmembrane efflux pump well characterised in drug resistant cancer cells [6]. We hypothesized that Pgp1 may play a role in steroid resistance and would be increased in peripheral

\* Correspondence: greg.hodge@health.sa.gov.au

<sup>1</sup>Lung Research, Hanson Institute and Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, South Australia

<sup>2</sup>Department of Medicine, University of Adelaide, Adelaide, South Australia

blood T, NKT-like and NK cells in patients with COPD, and that this would be accompanied by increased expression of IFN $\gamma$ , TNF $\alpha$  and granzyme B. We further hypothesized that treatment with low dose cyclosporine A, a Pgp1 inhibitor, would render cells more sensitive to treatment with corticosteroids.

Pgp1, granzyme B, IFN $\gamma$  and TNF $\alpha$  expression were measured in peripheral blood T, NK and NKT-like cells from COPD patients and control subjects ( $\pm$  cyclosporine A and prednisolone) following *in vitro* stimulation and results correlated with uptake of efflux dye calcein AM using flow cytometry.

## Methods

### Patient and control groups

COPD patients and controls were recruited for the study and fully informed consent obtained. There was no exacerbation of COPD for 6 weeks prior to involvement in the study. Ethics approval was obtained from the Royal Adelaide Hospital. The diagnosis of moderate COPD was established using the GOLD criteria [7] of a relevant history and post bronchodilator FEV1 30-80% of predicted and FEV1/FVC < 70%.

Blood was collected from 10 patients with COPD (Table 1) of whom all were ex-smokers (at least one year).

Blood was also obtained from 14 non-smoking volunteers (Table 1) with no history of airways disease and normal lung function).

### Leucocyte counts

Full blood counts, including white cell differential counts, were determined on blood specimens using a CELL-DYN 4000 (Abbot Diagnostics, Sydney, Australia). Blood films were stained by the May-Grunwald-Giemsa method and white cell differential counts checked by morphological assessment microscopically.

### CD3, CD4 and CD8 cell counts

The percentages of CD3, CD4 and CD8 lymphocytes were calculated using flow cytometry. One hundred microlitre of peripheral blood were stained with appropriately

diluted fluorescently conjugated monoclonal antibodies as previously described [3].

### Granzyme B expression by T, NKT-like and NK cells

The percentages of T, NKT-like and NK cells expressing granzyme B, was determined as previously reported [5].

### Leucocyte stimulation

Leucocyte stimulation was required for both intracellular cytokine and Pgp1 expression by T, NKT-like and NK cells. One mL aliquots of blood (diluted 1:2 with RPMI 1640 medium) were placed in a 10 mL sterile conical PVC tubes (Johns Professional Products, Sydney, Australia). Phorbol myristate (25 ng/mL) (Sigma, Sydney, Australia) and ionomycin (1  $\mu$ g/mL) (Sigma) was added. Brefeldin A (10  $\mu$ g/mL) was added as a "Golgi block" (Sigma) and the tubes re-incubated in a humidified 5% CO $_2$ /95% air atmosphere at 37°C for 16 h.

### Intracellular IFN $\gamma$ and TNF $\alpha$ expression by T, NKT-like and NK cells

Three hundred and fifty  $\mu$ L of stimulated peripheral blood cells were stained with appropriately diluted fluorescently conjugated monoclonal antibodies as previously reported [3-5] to IFN $\gamma$  FITC (BD Biosciences, Sydney, Australia) (BD), CD3 perCP.Cy5.5 (BD), CD56 APC (Beckman Coulter, Sydney, Australia), TNF $\alpha$  V450, granzyme B V450 and CD45 V500 (BD). Samples were analysed by gating using forward scatter (FSC) versus side scatter (SSC) to exclude platelets and debris. Gated cells were analysed with CD45 V500 (BD) to ascertain that cells were of lymphoid origin. A minimum of 500,000 CD45 positive, low SSC events were acquired on a FACSCanto II (BD) in list-mode format for analysis using FACSDiva software (BD). T cells were identified as events that were CD3 + CD56-, NK cells as CD3-CD56+ and NKT-like cells as CD3 + CD56+ events as previously reported [5].

### Pgp1 expression by T, NK and NKT-like cells

Preliminary experiments showed that cells required stimulation for significant Pgp1 molecule expression by T, NKT-like and NK cells. Following stimulation as described above, 350  $\mu$ L aliquots of cells were treated with 2 mL FACSLyse for 10 min. Cells were centrifuged, supernatant discarded and 500 mL FACSPerm added for 10 min. Two mL 0.5% bovine serum albumin (BSA) (Sigma) in IsoFlow (Beckman Coulter) was then added and the tubes centrifuged at 300 g for 5 min. After decanting supernatant, Fc receptors were blocked with 10 mL human immunoglobulin (Intragam, CSL, Melbourne, Australia) for 10 min at room temperature. Five  $\mu$ L of appropriately diluted CD3 perCP.Cy5.5 (BD), Pgp1 PE (BD) CD56 APC (Beckman Coulter) and CD45 V500 (BD) or isotype

**Table 1 Demographic details of the COPD and control subjects**

Subjects	Controls	COPD
No. of subjects	14	10
Age (years)	56 ( $\pm$ 8)	58 ( $\pm$ 16)
FEV1, % pred	110.4 ( $\pm$ 9)	60.5 ( $\pm$ 20)
FEV1, % FVC	96 ( $\pm$ 12)	58 ( $\pm$ 15)*
Male/Female	8/6	6/4

Data shown as mean  $\pm$  SEM.

Abbreviations: COPD: chronic obstructive pulmonary disease. FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; \*P < 0.05 compared to controls.

control (BD) were added for 15 min in the dark at room temperature. Cells were washed and events acquired and analyzed as described above.

#### **Pgp1, IFN $\gamma$ , TNF $\alpha$ and granzyme B expression by T, NKT-like and NK cells**

To determine possible association of pro-inflammatory cytokines and granzyme B expression with Pgp1 expression by T, NKT-like and NK cells, whole blood was stimulated as described above. Following stimulation and processing, 5  $\mu$ L of appropriately diluted IFN $\gamma$  FITC (BD), granzyme B FITC (BD), Pgp1 PE (BD), CD3 perCP.Cy5.5 (BD), TNF $\alpha$  V450 (BD) and CD45 V500 (BD) were added for 15 min in the dark at room temperature. Cells were washed and events acquired and analyzed as described above.

#### **Uptake of Calcein-AM by T, NKT-like and NK cells**

To determine functional Pgp1 activity, efflux of Calcein-AM was analysed in T, NKT-like and NK cells as previously published [8] from a cohort of COPD patients and control subjects. Briefly, following stimulation of cells as described above, 5 nM Calcein-AM (eBioscience, San Diego, CA, USA) was added and cells re-incubated in a humidified 5% CO<sub>2</sub>/95% air atmosphere at 37°C for 30 min. Aliquots were washed twice with wash buffer to remove free Calcein-AM and cells processed for Pgp1 expression as described above.

#### **Effect of methylprednisolone and Cyclosporin A on Pgp1, IFN $\gamma$ , TNF $\alpha$ and granzyme B expression by T, NKT-like and NK cells**

To determine the effects of methylprednisolone and Cyclosporin A on Pgp1, IFN $\gamma$ , TNF $\alpha$  and granzyme B expression by T, NKT-like and NK cell subsets, one mL aliquots of blood (diluted 1:2 with RPMI 1640 medium) were placed in a 10 mL sterile conical PVC tubes with 10<sup>-6</sup> M methylprednisolone and/or various concentrations of Cyclosporin A (0, 1, 2.5, 5, 10, 50, 100, 200 and 250 ng/mL) for 24 h in a humidified 5% CO<sub>2</sub>/95% air atmosphere at 37°C. Blood cultures were then stimulated as described above for 16 h and processed for Pgp1, IFN $\gamma$ , TNF $\alpha$ , granzyme B and perforin expression by T, NKT-like and NK subsets as described above.

#### **Statistical analysis**

Statistical analysis was performed using Mann–Whitney and Spearman Rho correlation tests using SPSS software and differences between groups of  $P < 0.05$  considered significant.


## **Results**

### **Blood CD4+ and CD8+ T cell counts**

There was a significant increase in the absolute number of CD8 T cells in blood from COPD patients compared with controls ( $0.43 \pm 0.22$  and  $0.33 \pm 0.16 \times 10^9/L$  for COPD patients and controls respectively,  $P = 0.047$ ). There were no other significant differences in the absolute counts of CD3+, CD4+ or CD8+ absolute counts. The percentage of CD8+ T cells was significantly increased and CD4+ T cells significantly decreased in the COPD group compared to the control group ( $57 \pm 8$  and  $69 \pm 7$  for CD4 and  $43 \pm 9$  and  $31 \pm 8$  for CD8 for COPD patients and controls respectively,  $P = 0.032$  and  $P = 0.037$  respectively). The percentage of CD4-CD8- and CD4+CD8+ T cells was  $< 3\%$  for all patient and control subjects. There was no change in the percentage or absolute numbers of NK and NKT-like cells between COPD patients and control group ( $p < 0.05$  for all) consistent with our previous report [9] (data not shown).

### **Pgp1 expression by T, NKT-like and NK cells**

There was no significant differences in Pgp1 expression by stimulated CD3+ T cells (Figure 1). There was however a significant increase in Pgp1 expression by NKT-like and NK cells from COPD patients versus controls (Figure 1). Pgp1 expression was higher in NKT-like and NK cells than T cells for COPD patients but not control subjects ( $p > 0.05$  for all).



**Figure 1 Pgp1 + T, NKT-like and NK cells in COPD and control subjects.** Data presented as box plots. There was a significant increase in the percentage of Pgp1 + NKT-like and Pgp1 + NK cells in COPD patients (grey bars) compared with control subjects (clear bars). The percentage of Pgp1 + NKT-like and Pgp1 + NK cells was greater than the percentage of Pgp1 + T cells for COPD patients but not control subjects ( $p > 0.05$  for all).

### IFN $\gamma$ , TNF $\alpha$ and granzyme B expression by T, NKT-like and NK cells

There was no significant increase in IFN $\gamma$  expression by stimulated CD3 $^{+}$  T cells from COPD patients versus controls (Figure 2a). There was however a significant increase in IFN $\gamma$  expression by NKT-like and NK cells in COPD patients compared with controls (Figure 2a).

There was a significant increase in both TNF $\alpha$  and granzyme B expression by CD3 $^{+}$  T, NKT-like and NK cells in COPD patients compared with controls (Figure 2b and 2c).

### IFN $\gamma$ , TNF $\alpha$ and granzyme B expression by Pgp1 $^{+}$ T, NKT-like and NK cells


There was a significant increase in IFN $\gamma$ , TNF $\alpha$  and granzyme B expression by Pgp1 $^{+}$  T, NKT-like and NK cells in COPD patients compared with controls (Figure 3a, 3b and 3c). Granzyme B expression was significantly increased in stimulated T, NKT-like and NK cells from both COPD patients and controls compared with non-stimulated blood ( $p < 0.05$  for all) (data not shown). Representative dot plots showing increased IFN $\gamma$  expression by Pgp1 $^{+}$  T, NKT-like and NK cells from a patient with COPD compared with a control subject are shown in Figure 4.


### Correlation between Pgp-1 expression and Calcein-AM expression by T, NKT-like and NK cells

Calcein-AM has been shown to enter cells that are deficient in Pgp1 expression [8]. There was a significant negative correlation between Pgp1 expression and Calcein-AM uptake by T ( $R = .893$ ,  $p = .012$ ) (Figure 5), NKT-like ( $R = .901$ ,  $p = .008$ ) and NK cells ( $R = .915$ ,  $p = .004$ ) from a cohort of 6 COPD patients and 6 control subjects.

### Effect of methylprednisolone and Cyclosporin A on Pgp1, IFN $\gamma$ , TNF $\alpha$ and granzyme B expression by T, NKT-like and NK cells

The inhibitory effect of  $10^{-6}$  M methylprednisolone alone and in combination with 2.5 ng/mL Cyclosporin A on Pgp1, IFN $\gamma$ , TNF $\alpha$  and granzyme B expression by T, NKT-like and NK cells are shown in Table 2. The inhibitory effect of  $10^{-6}$  M methylprednisolone on IFN $\gamma$  and TNF $\alpha$  expression by NK cells was greater than for T and NKT-like cells. In the presence of 2.5 ng/mL Cyclosporin A there was a significant inhibition of IFN $\gamma$  and TNF $\alpha$  expression by all subsets. The combination of  $10^{-6}$  M methylprednisolone and 2.5 ng/mL Cyclosporin A resulted in a synergistic inhibition of IFN $\gamma$  and TNF $\alpha$  expression by T and NKT-like cells. Representative plots showing the combined inhibitory effect of  $10^{-6}$  M methylprednisolone and 2.5 ng/mL Cyclosporin A on IFN $\gamma$  expression by Pgp1 $^{+}$  T and NKT-like cells are shown in Figure 6. Higher concentrations of Cyclosporin A ( $>10$  ng/mL) resulted in almost complete inhibition of IFN $\gamma$  and TNF $\alpha$  expression by T, NKT-like and NK cells (data not shown). There was no inhibitory effect of  $10^{-6}$  M methylprednisolone on granzyme B expression by T, NKT-like and NK cells. Significant inhibition of granzyme B expression by T, NKT-like and NK cells was only noted in the presence of 200 ng/mL and 250 ng/mL Cyclosporin A (e.g.,  $10 \pm 4$ ,  $1 \pm 2$ ,  $4 \pm 3\%$  inhibition of granzyme B in the presence of 200 ng/mL Cyclosporin A and  $28 \pm 8$ ,  $6 \pm 4$ ,  $18 \pm 6\%$  inhibition of granzyme B in the presence of 250 ng/mL Cyclosporin A by T, NKT-like and NK cells respectively). The addition of  $10^{-6}$  M methylprednisolone resulted in no additional effect on Pgp1 expression by any cell subset (data not shown). To determine the association of Pgp1 expression with drug resistance, the inhibitory effect of the various drug combinations on IFN $\gamma$  and TNF $\alpha$  expression by Pgp1 $^{+}$  T, NKT-like and NK cells was







investigated and results were almost identical to those for total IFN $\gamma$  and TNF $\alpha$  expression by Pgp1+ T, NKT-like and NK cells (Table 3) and suggests a strong association between Pgp1 expression and drug resistance in T, NKT-like and NK cells.

### Discussion

This is the first study to show differential expression of the drug efflux pump Pgp1 by T, NKT-like and NK cells from COPD patients compared with healthy control subjects. COPD is a systemic disease [2] and we have





**Figure 5 Correlation between Calcein-AM and Pgp1 in T cells.**  
 Graph of Calcein-AM + CD3+ versus Pgp1 + CD3+ T cells. There was a significant negative correlation between Pgp1 expression and Calcein-AM uptake by CD3+ T cells from a cohort of 6 COPD patients and 6 control subjects.

previously shown increased IFN $\gamma$  and TNF $\alpha$  by T cells [3], granzyme B by NK and NKT-like cells [5] and granzyme B by T cells [4] in the peripheral blood and lungs of COPD patients. Our novel findings that Pgp1 is up-regulated in NKT-like and NK cells in patients with COPD and that this is associated with increased pro-inflammatory and cytotoxic molecules in T, NKT-like and NK cells have important implications for treatment strategies to target these cells.

The relative lack of corticosteroid efficacy in COPD has been poorly understood and a major limiting factor in COPD treatment [2]. We now show that production of IFN $\gamma$  and TNF $\alpha$  and granzyme B by T and NKT-like subsets of lymphocytes are not inhibited with therapeutic doses of methylprednisolone, a commonly used corticosteroid *in vitro*, confirming clinical findings. Importantly we show that by targeting Pgp1 with a low dose of the inhibitor, cyclosporine A, production of the pro-inflammatory cytokines IFN $\gamma$  and TNF $\alpha$  are significantly inhibited. Further, a combination of very low dose cyclosporine A (2.5 ng/mL) with standard dose methylprednisolone (10<sup>-6</sup> M), results in synergistic inhibition of

these pro-inflammatory cytokines known to have systemic effects in patients with COPD [2]. The excellent negative correlation between efflux of Calcein-AM, previously shown to identify Pgp1 function in cells [8] and our findings of Pgp1 expression in T, NKT-like and NK cells confirms these novel findings.

Our group has undertaken pioneering work on the role of T-cell pro-inflammatory cytokines, particularly TNF $\alpha$  and IFN $\gamma$ , and their role in COPD [3]. T cells are a major inflammatory cell type present in the lung in COPD patients. Our findings in 2007 were the first comprehensive report of intracellular pro- and anti-inflammatory T cell cytokines in the separate compartments of blood, bronchoalveolar lavage and intraepithelial T cells from bronchial brushings from COPD subjects and smokers. Interestingly, T-cell derived TNF $\alpha$  has been shown to cause apoptosis of airway epithelial cells and impair the clearance of these cells by alveolar macrophages [10]. Recently, TNF $\alpha$  has been described as the “driving force behind COPD” [11], and induction of TNF $\alpha$  in the lung has been shown to result in emphysema in the mouse model [9]. TNF $\alpha$  has also been shown to induce IL-2Rs and IFN $\gamma$  production by T cells and activate neutrophils, macrophages, endothelial cells and fibroblasts [12]; cells that play important roles in the pathogenesis of COPD [2]. Recently it has been shown that fractalkine, a potent chemoattractant for monocytes and T cells produced by airway smooth muscle cells, was induced in the presence of both IFN $\gamma$  and TNF $\alpha$  [13]. Furthermore, increased TNF $\alpha$  levels have been shown to be increased in diseases associated with COPD such as cardiovascular disease and as such, systemic treatment with low dose Cyclosporin A and prednisolone may result in improvements of a broad range of inflammatory conditions associated with COPD [14].


An important extension of this work would be to study T, NKT-like and NK cells in both the airways and lung tissue of COPD patients as we have previously done [5,15] to determine the role Pgp1 may play in steroid resistance in these compartments. If this hypothesis is correct, targeting the airways with inhaled low dose CsA combined with steroid may be the treatment of choice to inhibit these pro-inflammatory molecules associated with COPD disease.

**Table 2 The inhibitory effect of 10<sup>-6</sup> M methylprednisolone (MP) alone and in combination with 2.5 ng/mL Cyclosporin A (CsA) on IFN $\gamma$  and TNF $\alpha$  expression by T, NKT-like and NK cells are shown (mean  $\pm$  SEM)**

Drug	Dose of drug	IFN $\gamma$			TNF $\alpha$		
		T	NKT	NK	T	NKT	NK
MP	10 <sup>-6</sup> M	2 $\pm$ 2*	5 $\pm$ 3	44 $\pm$ 8	2 $\pm$ 2	3 $\pm$ 2	47 $\pm$ 9
CsA	2.5 ng/ml	47 $\pm$ 9	44 $\pm$ 7	91 $\pm$ 5	51 $\pm$ 6	31 $\pm$ 9	92 $\pm$ 8
MP + CsA	10 <sup>-6</sup> M + 2.5 ng/ml	88 $\pm$ 7	83 $\pm$ 7	96 $\pm$ 6	81 $\pm$ 7	76 $\pm$ 7	96 $\pm$ 8

The combination of 10<sup>-6</sup> M methylprednisolone and 2.5 ng/mL Cyclosporin A resulted in the synergistic inhibition of IFN $\gamma$  and TNF $\alpha$  expression by T and NKT-like cells.

\* The percentage inhibition of IFN $\gamma$  and TNF $\alpha$  by T, NKT-like and NK cells compared with control (same specimen) without drug/s.



It would also be of interest to study Pgp1 expression in lymphocyte subsets in the peripheral blood of smokers who have not progressed to COPD. Our previous findings of increased T-cell production of IFN $\gamma$  and TNF $\alpha$  in the peripheral blood of COPD patients but not smokers without COPD suggests Pgp1 may not be upregulated in smokers who have not progressed to COPD. However,

there may be a subset of susceptible smokers who do have increased Pgp1 in these cells who have an increased risk of developing COPD and further studies are warranted to investigate this hypothesis.

Our present findings show that there was a significant increase in Pgp1 expression by T and NKT-like cells compared with NK cells suggesting these subsets of

**Table 3** The inhibitory effect of  $10^{-6}$  M methylprednisolone (MP) alone and in combination with 2.5 ng/mL Cyclosporin A (CsA) on IFN $\gamma$  and TNF $\alpha$  expression by Pgp1+ T, NKT-like and NK cells are shown (mean  $\pm$  SEM)

Drug	Dose	IFN $\gamma$			TNF $\alpha$		
		T	NKT	NK	T	NKT	NK
MP	$10^{-6}$ M	2 $\pm$ 2*	4 $\pm$ 3	45 $\pm$ 9	3 $\pm$ 2	5 $\pm$ 2	49 $\pm$ 9
CsA	2.5 ng/ml	50 $\pm$ 10	46 $\pm$ 8	89 $\pm$ 7	54 $\pm$ 6	27 $\pm$ 6	87 $\pm$ 7
MP + CsA	$10^{-6}$ M + 2.5 ng/ml	81 $\pm$ 5	76 $\pm$ 8	96 $\pm$ 7	78 $\pm$ 7	72 $\pm$ 8	97 $\pm$ 9

The combination of  $10^{-6}$  M methylprednisolone and 2.5 ng/mL Cyclosporin A resulted in the synergistic inhibition of IFN $\gamma$  and TNF $\alpha$  expression by Pgp1+ T and NKT-like cells.

\* The percentage inhibition of IFN $\gamma$  and TNF $\alpha$  by Pgp1+ T, NKT-like and NK cells compared with control (same specimen) without drug/s.



lymphocytes may be the most resistant to effects of therapeutic drugs.

We showed that the cytotoxic molecule, granzyme B is unaltered by standard dose methylprednisolone and requires much higher concentrations of cyclosporine usually used for immunosuppression in patients such as those following lung transplantation [16]. Our results suggest that patients with high levels of this cytotoxic molecule may require treatment with higher dose Cyclosporin A. Further, identification of patients with high levels of granzyme B and response following treatment may allow tailoring therapeutics to individual patients using these techniques, to optimize immunosuppression as to possibly avoid problems associated with over-immunosuppression (e.g., infection and malignancy) and under-immunosuppression with worsening of COPD symptoms.

## Conclusion

In conclusion, COPD is associated with increased Pgp1 expression by peripheral blood T, NKT-like and NK cells co-expressing IFN $\gamma$ , TNF $\alpha$  and granzyme B. Treatment strategies that target Pgp1 in T, NKT-like and NK cells may reduce systemic inflammatory mediators in COPD and improve patient morbidity.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

GH performed the concept and design of experiments, analysis and interpretation of data and manuscript preparation; MH supplied and characterized patient specimens and helped draft the manuscript; HJ supplied and characterized patient specimens and helped draft the manuscript; PNR supplied and characterized patient specimens and helped draft the manuscript; SH helped with study design, statistical analysis and helped draft the manuscript. All authors read and approved the final manuscript.

## Acknowledgements

The authors acknowledge Miss Jessica Ahern for expert technical assistance. This study was funded by a Royal Adelaide Hospital Research Fund grant and a Lung Foundation Australia/Boehringer Ingelheim COPD Research Fellowship.

Received: 19 February 2013 Accepted: 15 May 2013

Published: 3 June 2013

## References

1. Barnes PJ, Adcock IM: Glucocorticoid resistance in inflammatory diseases. *Lancet* 2009, **373**:1905–1917.
2. Barnes PJ, Celli BR: Systemic manifestations and comorbidities of COPD. *Eur Respir J* 2009, **33**:1165–1185.
3. Hodge G, Nairn J, Holmes M, Reynolds P, Hodge S: Increased intracellular Th1 pro-inflammatory cytokine production in peripheral blood, bronchoalveolar lavage and intraepithelial T cells of COPD subjects. *Clin Exp Immunol* 2007, **150**:22–29.
4. Hodge S, Hodge G, Nairn J, Holmes M, Reynolds PN: Increased airway granzyme B and perforin in current and ex-smoking COPD subjects. *COPD* 2006, **3**(4):179–187.
5. Hodge G, Mukaro V, Holmes M, Reynolds PN, Hodge S: Enhanced cytotoxic function of NK and NKT-like cells is associated with decreased CD94 (Kp43) in the COPD airway. *Respirology* 2013, **18**(2):369–376.

6. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM: Expression of a multidrug resistant gene in human tumors and tissues. *Proc Natl Acad Sci U S A* 1987, **84**:265–269.
7. Global Initiative for Chronic Obstructive Lung Disease: *Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease*. 2011. Available at <http://www.goldcopd.org/>.
8. Legrand O, Simonon S, Perrot J, Zittoun R, Marie J: Pgp and MRP activities using Calcein-AM are prognostic factors in adult acute myeloid leukemia. *Blood* 1998, **12**:4480–4488.
9. Chung A, Wang RD, Tai H, Wang X, Xie C, Wright JL: Tumour necrosis factor alpha drives 70% of cigarette smoke-induced emphysema in the mouse. *Am J Respir Care Med* 2004, **170**:492–498.
10. Vanderveer RW, Henson PM, Douglas IS: Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. *Chest* 2006, **129**(6):1673–1682.
11. Sevenoaks MJ, Stockley RA: Chronic obstructive pulmonary disease, inflammation and co-morbidity- a common inflammatory phenotype? *Resp Res* 2006, **7**:70.
12. Aggarwal BB: Tumour Necrosis Factor. In *Human cytokines*. 2nd edition. Edited by Aggarwal BB, Gutterman JU. Cambridge, Massachusetts: Blackwell Science; 1995:282–283.
13. Sukkar MB, Issa R, Xie S, Oltmanns U, Newton R, Chung KF: Fractaline/CX3CL1 production by human airway smooth muscle cells: induction by IFN-gamma and TNF-alpha and regulation by TGF-beta and corticosteroids. *Am J Physiol Lung Cell Mol Physiol* 2004, **287**:1230–1240.
14. Safranow K, Dziedziczko V, Rzeuski R, Czyzowska E, Wojtarowicz A: Plasma concentrations of TNF-alpha and its soluble receptors sTNFR1 and sTNFR2 in patients with coronary artery disease. *Tissue Antigens* 2009, **74**(5):386–392.
15. Soriano C, Mukaro V, Hodge G, Ahern J, Holmes M, Jersmann H, Moffat D, Meredith D, Jurisevic C, Reynolds PN, Hodge S: Increased proteinase inhibitor-9 (PI-9) and reduced granzyme B in lung cancer: mechanism for immune evasion? *Lung Cancer* 2012, **77**(1):38–45.
16. Citterio F: Evolution of the therapeutic drug monitoring of cyclosporine. *Transplant Proc* 2004, **36**:420S–425S.

doi:10.1186/1465-9921-14-63

**Cite this article as:** Hodge et al.: The drug efflux pump Pgp1 in pro-inflammatory lymphocytes is a target for novel treatment strategies in COPD. *Respiratory Research* 2013 **14**:63.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

